Molecular basis of AML
2010-06-11 - English

The Platelet sheddome
2010-06-11 - English

Thalassemia intermedia-treatment strategies
2010-06-11 - English

Biological functions and new developments of erythropoiesis-stimulating agents in management of anemia
2010-06-11 - English

How to detect and measure microparticles
2010-06-11 - English

Objectives of Presentation by Paul Harrison

1)Definition and Function of Microparticles

2)How to Measure Microparticles

3)New technologies for measuring Microparticles

4)Microparticles as potential biomarkers of different diseases

5)Summary and Future prospects

Genetic markers of prognosis in CLL
2010-06-11 - English

Hypercoagulability in Sickle Cell Disease
2010-06-11 - English

The significance of the hypercoagulable state of sickle cell disease.

Developments of novel therapies in MPD
2010-06-11 - English

Biological basis of PNH
2010-06-11 - English

Diagnosis & management of fungal infection
2010-06-11 - English

Assess the risk of morbidity and mortality due to invasive fungal infections in patients with hematological malignancies; select the appropriate risk-adapted approach to diagnose invasive fungal disease; choose the right antifungal treatment regimen according to the...(more)

GPVI shedding
2010-06-11 - English

Novel antibodies and immunomodulators for the therapy of CLL
2010-06-11 - English

Lessons from the PT-1 study
2010-06-11 - English

Vaccination post-transplant
2010-06-11 - English

Available data on efficacy of vaccination in stem cell transplant patients

Available data on safety of vaccination in stem cell transplant patients

Coagulation as a target for cancer therapy
2010-06-11 - English

Treatment of adult AML
2010-06-11 - English

Introduction
2010-06-11 - English

Role of oncogenic mutations and fusion genes in ALL
2010-06-11 - English

European registry
2010-06-11 - English

Impact of myeloma biology in disease outcome
2010-06-11 - English

PET in pediatric lymphoma
2010-06-11 - English

MRD oriented treatment in PH-adult ALL
2010-06-11 - English

The pros ans cons of the two main techniques for MRD evaluation and the vaule of MRD as a tool for decesions in Ph-negative ALL in adults

Molecular design of targeted therapy in Chronic Myelogenous Leukemia
2010-06-11 - English

Risk adapted treatment
2010-06-11 - English

After this presentation the participant will be able to discuss:

- Genetic events resulting in Myeloma.
- Effects of genetics events on prognosis.
- Ability of new drugs to overcome high risk genetics.
- Synthesizing genetic information in treatment planning.

Role of SCT in management of Myeloma
2010-06-11 - English

New targets and drugs in peripheral T-cell lymphoma
2010-06-11 - English

Treatment in PH-adult ALL
2010-06-11 - English

Type 3 von Willebrand disease
2010-06-11 - English

Objectives
1. the symptoms and impact on quality of life of Von Willebrand disease type 3
2. the diagnosis of type 3 von Willebrand disease and the value of genetic testing
3. the treatment of von Willebrand disease type 3

Treatment of disease complications and unusual forms of myeloma
2010-06-11 - English

Management of MDS
2010-06-11 - English

PET-network for clinical trials
2010-06-11 - English

Clinical trials in transfusion medicine
2010-06-11 - English

Summary
Clinical trials, especially randomized controlled trials (RCT) and carefully conducted observational trials, provide the evidence necessary for appropriate decision-making. Transfusion medicine has become a clinical discipline relatively recently, which explains...(more)

Opening Address
2010-06-11 - English

José Carreras Lecture: Introduction
2010-06-11 - English

DASATINIB COMPARED TO IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP): RESULTS FROM THE RANDOMIZED PHASE 3 DASISION TRIA
2010-06-12 - English

ZOLEDRONIC ACID (ZOL) PROLONGS TIME TO FIRST SKELETAL-RELATED EVENT (SRE) AND SURVIVAL VERSUS CLODRONATE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): MRC MYELOMA IX TRIAL RESULTS
2010-06-12 - English

INACTIVATING MUTATIONS OF THE HISTONE METHYLTRANSFERASE EZH2 ARE ASSOCIATED WITH CHROMOSOME 7 ABNORMALITIES IN MYELOID DISORDERS
2010-06-12 - English

Abnormalities of chromosome 7q are common in myeloid malignancies but no specific target genes have been identified. Recently, we and others reported that 7q acquired uniparental disomy (aUPD) is seen in MDS/MPN and MDS but is uncommon in AML. To identify further cases with...(more)